Founded by scientists associated with the University of Wroclaw and further developed through collaborative synergy with esteemed investment and biotechnology specialists.
Founded by scientists associated with the University of Wroclaw and further developed through collaborative synergy with esteemed investment and biotechnology specialists.
Founded by scientists associated with the University of Wroclaw and further developed through collaborative synergy with esteemed investment and biotechnology specialists.
Together, we're dedicated to developing an innovative antibody-drug conjugate for the treatment of lung and breast cancer with precision and efficacy.
Meet our team
Aleksandra Sokołowska-Wędzina, PhD
Aleksandra Sokołowska-Wędzina
PhD
Co-founder
Scientist, Protein Engineering Department, University of Wrocław
Jacek Otlewski
PhD
Co-founder
Scientist, Protein Engineering Department, University of Wrocław
Our Core Strengths
Highly qualified scientific and management team with extensive experience
With support from experienced advisory team
Methodology for molecular target selection and antibody characterization
Designed to deliver toxins exclusively to the cancer cells
World-class know-how in recombinant protein engineering and production
Precise characterization of obtained proteins
Experience in the production and testing of Antibody-Drug Conjugates (ADCs)
ADC development with our in-house platform
Our Core Strengths
Highly qualified scientific and management team with extensive experience
With support from experienced advisory team
Methodology for molecular target selection and antibody characterization
Designed to deliver toxins exclusively to the cancer cells
World-class know-how in recombinant protein engineering and production
Precise characterization of obtained proteins
Experience in the production and testing of Antibody-Drug Conjugates (ADCs)
ADC development with our in-house platform
Our Core Strengths
Highly qualified scientific and management team with extensive experience
With support from experienced advisory team
Methodology for molecular target selection and antibody characterization
Designed to deliver toxins exclusively to the cancer cells
World-class know-how in recombinant protein engineering and production
Precise characterization of obtained proteins
Experience in the production and testing of Antibody-Drug Conjugates (ADCs)
ADC development with our in-house platform
Our goal is to provide patients with empowering, cutting-edge treatment solutions
Our goal is to provide patients with empowering, cutting-edge treatment solutions
Our goal is to provide patients with empowering, cutting-edge treatment solutions
Fueling the future of precision oncology
Join us in advancing precision oncology—invest in groundbreaking science that delivers safer, more effective cancer treatments for patients worldwide.
Fueling the future of precision oncology
Join us in advancing precision oncology—invest in groundbreaking science that delivers safer, more effective cancer treatments for patients worldwide.
Fueling the future of precision oncology
Join us in advancing precision oncology—invest in groundbreaking science that delivers safer, more effective cancer treatments for patients worldwide.
About
Onconick specializes in precision oncology, developing new antibody-drug conjugates (ADCs) targeting highly specific novel markers in challenging cancer types.
© 2025 Onconick. All rights reserved.
About
Onconick specializes in precision oncology, developing new antibody-drug conjugates (ADCs) targeting highly specific novel markers in challenging cancer types.
© 2025 Onconick. All rights reserved.
About
Onconick specializes in precision oncology, developing new antibody-drug conjugates (ADCs) targeting highly specific novel markers in challenging cancer types.
© 2025 Onconick. All rights reserved.